Trospium chloride - TARIS Biomedical
Alternative Names: TAR-302; TAR-302-5018Latest Information Update: 28 Jul 2020
At a glance
- Originator TARIS Biomedical
- Class Antispasmodics; Benzhydryl compounds; Benzilates; Esters; Nortropanes; Small molecules; Spiro compounds; Urologics
- Mechanism of Action Cholinergic receptor antagonists; Muscarinic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Neurogenic bladder; Overactive bladder
Most Recent Events
- 28 Jul 2020 No recent reports of development identified for phase-I development in Neurogenic-bladder in USA (Intravesicular)
- 28 Jul 2020 No recent reports of development identified for phase-I development in Overactive bladder in USA (Intravesicular)
- 15 May 2020 Efficacy and adverse events data from a phase I trial in Overactive bladder presented at the 115th Annual Meeting of the American Urological Association (AUA-2020)